Literature DB >> 455894

Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: a kinetic approach.

P R Martin, C M Bhushan, B M Kapur, E A Whiteside, E M Sellers.   

Abstract

Phenobarbital (0.03 to 0.04 mg/kg/min) was infused intravenously in 7 patients with clinical hypnosedative withdrawal reaction until patients slept but were arousable. The infusion time to reach this clinical end point was 7.8 +/- 1.1 hr (mean +/- SEM), the total dose was 992 +/- 144 mg, and the peak serum phenobarbital concentration was 26.1 +/- 5.1 micrograms/ml. A user of minimal hypnosedatives required 54% less phenobarbital and 65% lower concentration than any of the abusers to reach an equivalent state of intoxication. The mean serum half-life (t 1/2) was 57.5 +/- 4.9 hr for hypnosedative abusers and 86 +/- 3 hr for 8 normal volunteers (p less than 0.001). Only the patient with the shortest t 1/2 (36.4 hr) required oral phenobarbital supplements to prevent withdrawal symptoms. Dosage supplements required can be calculated from the postinfusion rate of fall of serum phenobarbital. Slow infusion of large amounts of phenobarbital provides a safe, efficacious single-dose treatment.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 455894     DOI: 10.1002/cpt1979262256

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Oral phenobarbital loading: a safe method of barbiturate and nonbarbiturate hypnosedative withdrawal.

Authors:  E Janecek; B M Kapur; P Devenyi
Journal:  CMAJ       Date:  1987-09-01       Impact factor: 8.262

Review 2.  Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective.

Authors:  U Busto; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

3.  Pharmacokinetics of phenobarbital in the cat following multiple oral administration.

Authors:  S M Cochrane; J M Parent; W D Black; D G Allen; J H Lumsden
Journal:  Can J Vet Res       Date:  1990-06       Impact factor: 1.310

4.  Catecholamine metabolism during clonidine withdrawal.

Authors:  P R Martin; M H Ebert; E K Gordon; H Weingartner; I J Kopin
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 5.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 6.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 7.  Pharmacokinetics of drug overdose.

Authors:  J Rosenberg; N L Benowitz; S Pond
Journal:  Clin Pharmacokinet       Date:  1981 May-Jun       Impact factor: 6.447

8.  Pharmacokinetics of phenobarbital in the cat following intravenous and oral administration.

Authors:  S M Cochrane; W D Black; J M Parent; D G Allen; J H Lumsden
Journal:  Can J Vet Res       Date:  1990-01       Impact factor: 1.310

9.  Kinetics of phenobarbital in normal subjects and epileptic patients.

Authors:  A J Wilensky; P N Friel; R H Levy; C P Comfort; S P Kaluzny
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.